Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Cytokine ; 113: 285-290, 2019 01.
Article in English | MEDLINE | ID: mdl-30037707

ABSTRACT

This study investigated the efficacy of the vaccine in liver of mice infected with the Trypanosoma cruzi (T. cruzi) and immunized with AdASP-2. For this purpose, histopathological analysis and gene expression of COX-2, TNF-alpha, TNFR, iNOS, cytochrome C, caspase-3, TLR4, IL-6 and IL10 were evaluated. The following groups were used in this study: Group 1 - Control Group (CTRL) animals received AdßGal vehicle; Group 2 - Infected Group (TC) animals were infected with T. cruzi; Group 3 - Immunized Group (AdASP-2): animals were immunized by AdASP-2 vaccine; Group 4 - Immunized and Infected Group (AdASP-2+TC) animals were infected with T. cruzi and immunized by AdSP-2 vaccine. A significant decrease of amastigote nests was noticed in the group of animals that were immunized with AdASP-2 and infected on the same day. COX-2 and TNF-alpha gene expressions increased in TC group, whereas TNF-alpha decreased in the TC+AdASP-2 group. TNFR expression was high in AdASP-2+TC group. iNOS expression was high for all experimental groups whereas cytochrome C decreased for all experimental groups. Caspase 3 increased in TC and TC+AdASP-2 groups. The gene expression of TLR4 and IL-10 showed an increase in AdASP-2+TC group. Finally, hepatic fibrosis was noticed to TC and AdASP-2 + TC groups. Taken together, our results demonstrated that vaccination with AdASP-2 was effective against the acute phase of experimental Chagas disease as a result of a more powerful and rapid immune response closely related to expression of some inflammatory genes, such as iNOS, TNF-alpha, TLR 4, and IL-10.


Subject(s)
Chagas Cardiomyopathy/immunology , Liver Cirrhosis/immunology , Liver/immunology , Neuraminidase/immunology , Protozoan Vaccines/immunology , Trypanosoma cruzi/immunology , Adenoviridae , Animals , Caspase 3/immunology , Chagas Cardiomyopathy/parasitology , Chagas Cardiomyopathy/pathology , Chagas Cardiomyopathy/prevention & control , Cyclooxygenase 2/immunology , Cytochromes c/immunology , Cytokines/immunology , Female , Liver/parasitology , Liver/pathology , Liver Cirrhosis/parasitology , Liver Cirrhosis/pathology , Liver Cirrhosis/prevention & control , Mice , Nitric Oxide Synthase Type II/immunology , Toll-Like Receptor 4/immunology
2.
Hum Vaccin Immunother ; 10(10): 2864-74, 2014.
Article in English | MEDLINE | ID: mdl-25483465

ABSTRACT

E. coli O111 strains are responsible for outbreaks of blood diarrhea and hemolytic uremic syndrome throughout the world. Because of their phenotypic variability, the development of a vaccine against these strains which targets an antigen that is common to all of them is quite a challenge. Previous results have indicated, however, that O111 LPS is such a candidate, but its toxicity makes LPS forbidden for human use. To overcome this problem, O111 polysaccharides were conjugated either to cytochrome C or to EtxB (a recombinant B subunit of LT) as carrier proteins. The O111-cytochrome C conjugate was incorporated in silica SBA-15 nanoparticles and administered subcutaneously in rabbits, while the O111-EtxB conjugate was incorporated in Vaxcine(TM), an oil-based delivery system, and administered orally in mice. The results showed that one year post-vaccination, the conjugate incorporated in silica SBA-15 generated antibodies in rabbits able to inhibit the adhesion of all categories of O111 E. coli to epithelial cells. Importantly, mice immunized orally with the O111-EtxB conjugate in Vaxcine(TM) generated systemic and mucosal humoral responses against all categories of O111 E. coli as well as antibodies able to inhibit the toxic effect of LT in vitro. In summary, the results obtained by using 2 different approaches indicate that a vaccine that targets the O111 antigen has the potential to prevent diarrhea induced by O111 E. coli strains regardless their mechanism of virulence. They also suggest that a conjugated vaccine that uses EtxB as a carrier protein has potential to combat diarrhea induced by ETEC.


Subject(s)
Antibodies, Bacterial/blood , Drug Carriers/therapeutic use , Escherichia coli Infections/prevention & control , Escherichia coli/immunology , Polysaccharides, Bacterial/immunology , Vaccines, Conjugate/immunology , Animals , Antibodies, Bacterial/immunology , Bacterial Adhesion/immunology , Bacterial Toxins/chemistry , Bacterial Toxins/immunology , Cell Line , Cytochromes c/chemistry , Cytochromes c/immunology , Endotoxins/immunology , Enterotoxins/chemistry , Enterotoxins/immunology , Escherichia coli/classification , Escherichia coli Infections/immunology , Escherichia coli Infections/microbiology , Escherichia coli Proteins/chemistry , Escherichia coli Proteins/immunology , Female , Hemolytic-Uremic Syndrome/immunology , Hemolytic-Uremic Syndrome/microbiology , Hemolytic-Uremic Syndrome/prevention & control , Humans , Male , Mice , Mice, Inbred BALB C , Nanoparticles/therapeutic use , Rabbits , Silicon Dioxide/chemistry , Vaccines, Conjugate/therapeutic use
3.
Cytometry A ; 69(6): 515-23, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16680678

ABSTRACT

BACKGROUND: Cytochrome c release from mitochondria to cytosol is a hallmark of apoptosis and is used to characterize the mitochondria-dependent pathway of this type of cell death. Techniques currently used to measure cytochrome c release, Western blot and fluorescence microscopy of immunolabeled cells, are time-consuming and inaccurate, and the latter is still limited by sample size. METHODS: We developed a rapid and reliable technique to detect cytochrome c release during drug-induced apoptosis, using flow cytometry. Plasma membrane of apoptotic HL-60 cells and thymocytes, treated with staurosporine and dexamethasone, respectively, were selectively permeabilized by digitonin at a low concentration. The released cytochrome c was quickly washed out from cells and that which remained in the mitochondria was immunolabeled after fixing the cells. RESULTS: The fraction of cells that retained their mitochondrial cytochrome c, or the highly fluorescent cells, gradually decreased so that after 4-8 h of drug treatment almost all the cells lost their cytochrome c and emerged as a population of low fluorescent cells. This was confirmed by parallel fluorescence microscopy of cells immunolabeled for cytochrome c. CONCLUSIONS: This technique allows the analysis of cytochrome c release from mitochondria of a large number of apoptotic cells in a short period of time and is proposed as an alternative to the methods currently used for this same purpose.


Subject(s)
Apoptosis , Cell Membrane Permeability , Cytochromes c/analysis , Flow Cytometry/methods , Fluorescent Antibody Technique/methods , Mitochondria/metabolism , Animals , Cell Membrane/drug effects , Cell Membrane/metabolism , Cell Membrane Permeability/drug effects , Cytochromes c/immunology , Cytochromes c/metabolism , Dexamethasone/metabolism , Dexamethasone/pharmacology , Digitonin/metabolism , Digitonin/pharmacology , Female , HL-60 Cells , Humans , Mitochondria/enzymology , Rats , Staurosporine/metabolism , Staurosporine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL